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From newborn screening for Phenylkentonurea (PKU) and thebirth dose of Hepatitis B vaccine to prostate and breast cancerscreening and pneumococcal immunization for older adults, the
science of health maintenance is multi-tiered and spans the lifetime of
an individual. Primary, secondary, and tertiary prevention strategies are
used in concert with each other to enable healthcare professionals and
their patients to sustain and improve the quality of life.
Primary Prevention
Primary prevention mainly involves interventions that are designed
to reduce the occurrence of a particular disease. For example, immu-
nizations are given year round to both adults and children to prevent
infectious diseases. Folic acid is recommended to pregnant mothers to
reduce the incidence of spinal cord defects in their newborns. In each
of these strategies, the person does not yet have the disease we are trying
to prevent and in most cases, may not even have any risk factors (e.g.
polio vaccination of children). However, in some cases, vaccination
may be used to prevent or mitigate comorbid conditions. For example,
people with diabetes should be offered the pneumococcal vaccine as
they are at increased risk of complications from pneumococcal
pneumonia.
Secondary Prevention
Secondary prevention is targeted at detecting disease in individuals
who may not yet be symptomatic. For example, osteoporosis, which
is often referred to as the “silent disease,” causes a progressive deterio-
ration of bone tissue, with a consequent increase in bone fragility and
susceptibility to fracture.  Since low bone mass has been shown to be
highly predicative of future fracture risk, one preventative strategy
includes using bone mineral density (BMD) scans to screen patients
for decreased bone mass. While central dual-energy X-ray
absorptiometry (DXA) of the femoral neck is currently the gold
standard for diagnosis of osteoporosis, peripheral tests are useful
preliminary screening tools that can help identify people who may have
osteoporosis.1,2  As such, pharmacists can play a critical role in
identification and referral of patients at risk for osteoporosis through
pharmacy based-BMD screening.
In recent years, many pharmacists have also launched point-of-care
screening programs to detect other health conditions such as diabetes,
high cholesterol and hypertension. The widespread use of blood
glucose meters, for example, has identified millions of people with
elevated fasting plasma blood glucose (FPG) indicative of diabetes,
before they were ever detected by a physician. It is important to note
that screening differs from diagnosis. A diagnosis can only be made by
a clinician licensed to diagnose, which a pharmacist is not. The results
of screening tests, however, often are the first step to establishing a
medical diagnosis. A diagnosis is usually made during an examination
when patients are symptomatic for the disease and/or more definitive
tests support the diagnosis. For
example, a skin test (purified
protein derivative (PPD)) posi-
tive for tuberculosis (TB) would
indicate a patient has been ex-
posed to the disease, but a chest
x-ray, sputum samples, and a
physical exam would be needed
to make the diagnosis of active
TB.
The importance of disease
screening programs has long
been advocated by the public
health sector. In recent years,
as community pharmacies have
been undergoing a transfor-
mation from product-orien-
tated services to patient-ori-
entated services, more
pharmacists are beginning to
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see the value of screening for disease in their practice sites. Since
community pharmacists see a wide variety of people in varying states
of health on a daily basis, they are in a good position to identify patients
at risk for diseases such as diabetes, hyperlipidemia, and hypertension.
While screening programs generally involve the application of rela-
tively simple and inexpensive tests, it important to first recognize
and appreciate some of the fundamental key elements that form the
basis behind screening.
Screening Programs
A number of criteria must be considered before a decision is made
to implement a screening program. To begin with, there are three
different types of screening programs.
Multiphasic screening
Multiphasic screening is defined as the use of two or more screening
tests together among large groups of people to screen for more than
one disease. For example, health fairs that conduct blood glucose,
cholesterol, and blood pressure screening could give a better point-in-
time cardiovascular risk assessment for people.
Mass screening
Mass screening simply refers to a screening test applied to a large
population without regard to risk factors. For example, setting up a
blood glucose check in the mall and then screening everyone who
inquires. This will likely yield less abnormal blood glucose values, but
is relatively inexpensive and easy to set-up. In fact, the U.S. Preventive
Services Task Force 3 and the American Diabetes Association (ADA)4
do not recommend mass blood glucose screenings in asymptomatic
individuals. This is because there are many false positives when the test
is applied to the general population, which has about a 7% prevalence
of diabetes, and there is insufficient evidence to support its cost
effectiveness. The U.S. Preventative Task Force suggests that screen-
ing in high risk individuals (i.e. family history of diabetes, BMI ³25 kg/
m2, etc) is more likely to identify individuals who would benefit from
early detection and treatment.
Selective Screening
Selective screening (also known as targeted screening) is applied
to subsets of the population that are known to be at high risk for
a disease or certain condition based on risk factors, such as family
history, age, race, environmental exposures, etc. This form of
screening would likely yield the greatest number of positive indi-
viduals, but requires that some people be turned away because they
don’t meet criteria. In fact, by increasing the prevalence of a disease
(i.e. screening in individuals with risk factors), the positive predicative
value (the proportion of people with a disease that screen positive
for a disease) of a test will increase. Pharmacists who engage in
screening programs should select patients based on risk factors
(either patient identified or from prescriptions suggestive of
comorbid risk factors). Some other factors that are important to
consider when planning a screening program for a large population
are listed in Figure 1.
Once a decision has been made to implement a screening program,
the next important issue to consider is what measuring instrument is
necessary for the screening. Ideally, a good screening test should be
simple, rapid, safe and inexpensive. Some examples of commonly used
instruments are questionnaires, point of care analyzers (e.g. blood
glucose meter), and equipment such as a blood pressure cuff and
sphygnomometer.
Screening Test Accuracy
Arguably the most important aspect of a screening test is its
accuracy. Accuracy, also known as validity, measures how close the
screening test result comes to the gold standard for that lab value. For
example, the FDA allows up to a 20% deviation from the true value
for blood glucose meters. Reliability, or precision, is defined as the
degree to which a measure or a result can be replicated. It is usually
measured by performing two or more independent measurements and
then comparing the findings. Lack of reliability is often due to human
error, such as performing manual blood pressure on an individual by
different people or if the test value naturally fluctuates, such as blood
pressure.
Any screening test can give you an incorrect result. The direction
of the error is important. Screening tests are used to classify individuals
as having or not having a specific disease. As such, true positives refer
to those who test positive for a disease and who actually have the disease.
On the other hand, people who test positive but do not have the disease
are called false positive. True negatives refer to those who test negative
and do not have the disease while people who test negative but have the
disease are called false negatives. Figure 2 represents graphically this
concept.
Sensitivity and Specificity of Tests
Once these four measures of validity are obtained, one can deter-
mine the sensitivity and specificity of the test. The sensitivity of a test
is the proportion of correct results among people who actually have the
disease. The specificity of a test is the proportion of correct results
among people who do not actually have the disease. There is a
relationship between sensitivity and specificity when considering the
cutoff points for a given test. Unlike the predictive value of a test,
sensitivity and specificity are not affected by the prevalence of a disease.
A cutoff point is the level above which you would say the test result
is positive. Unfortunately, most diseases do not have an absolute line
where you can divide those with disease and those without 100% of the
Figure 1: Considerations in Planning
a Screening Program
1. The disease or condition being screened should be a major
medical problem.
2. Acceptable treatment should be available for individuals with
the disease who are discovered through the screening process.
3. Access to health care facilities and services for follow-up should
be available.
4. The disease should have a recognized course, with early and
late stages of the disease being identifiable.
5. Tests and testing procedures should be acceptable to the gen-
eral public.
6. The natural history of the disease should be adequately under-
stood.
7. Policies and procedures should be determined to know who
should be referred for further testing or treatment.
8. The process should be simple enough to encourage large
groups of people to participate.
9. Screening should not be an occasional activity; it should be
conducted on an ongoing basis
Figure 2: Classification of a Test Result
Disease No Disease
Screen Positive a b
True Positive False Positive
Screen Negative c d
False Negative  True Negative
Sensitivity + Specificity = Validity
Accuracy = (a+d)/(a+b+c+d)
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time. The establishment of such cutoff points is a critical part of
planning an effective screening program. For example, the FPG for
a given patient may be in the high range for a population even though
that person may not be diabetic. Similarly, some diabetic individuals
who are at the lower end of the curve for the diseased group may also
have blood glucose values in the high normal range. This kind of
a distribution creates an overlap such that some healthy individuals
may have elevated blood glucose, and some diabetic patients may
have glucose levels in the lower range for the abnormal group. The
challenge now is to determine where to set the cut off points to
maximize both specificity and sensitivity. If we were to improve
sensitivity, the cut point used to classify individuals as diabetic
should be moved farther in the range of those that are not diabetic
(e.g. using 100 mg/dl instead of 126 mg/dl for FPG). Keep in mind,
the higher you set the cutoff, the more false negatives you will get.
With a very serious, rapidly progressive disease where a definitive
test is available, you might be content to screen a lot of people
positive who really don’t have the disease (false positive) rather than
miss a few who really have the disease (false negative). Diabetes
doesn’t have a different definitive second stage test (e.g. chest x-
ray after a positive PPD) and is not a rapidly progressive disease.
Thus, the cutoff for FPG screening is generally set at ³100 mg/dl
which still errors on the side of low false negatives, but is not too
low as to send an unacceptable number of people to their physicians
for a diabetes work-up who don’t have diabetes. The category of
FPG at 100-125 mg/dl is also known as impaired fasting glucose
(i.e. “pre-diabetes”). For diagnostic purposes, the level of 126 mg/
dl on different days with an associated risk factor is used. Table 1
gives the ADA recommendations for screening cutoffs. However,
if specificity was the focus, the cut point should be moved further
in the range typically associated with the disease (i.e. a higher
cutoff). Consider the traumatic emotional implications of a false
positive for an HIV test. When considering blood-glucose meters,
keep in mind the accuracy and precision listed on the package insert
are the machine compared to a laboratory standard, not actually to
the diagnosis of diabetes or non-diabetes. However, blood glucose
is assumed to be an excellent proxy for diabetes.
Since point-of-care devices that measure analytes can become
imprecise or inaccurate, quality control is important to maintain. The
Clinical Laboratory Improvement Act (CLIA) was established in
1988 and regulates certain testing equipment and testing sites.5 This
law was established to help ensure that patients’ lab test results are
accurate, reliable, and timely regardless of where they are performed.
The law defines a laboratory as “any facility that performs laboratory
testing on specimens derived from humans for the purpose of
providing information for the diagnosis, prevention, treatment of
disease, or assessment of health”. Three categories of tests have been
established: waived complexity, moderate complexity (including the
subcategory of provider-performed microscopy), and high complex-
ity. Waived tests refer to tests that are generally “safe for home use”
and are simple and accurate as to render likelihood of erroneous results
negligible. Pharmacies and pharmacists will only perform waived
Table 1. Pharmacist Provided Screenings in the Community Setting
Screening Example of Target Values Reference
Screening Tools
Blood Glucose Any Glucometer Relationship Normal Impaired Diabetes1 Diabetes Care 28:S37-S42, 2005
to Food Fasting
Glucose
Fasting
Plasma <100 mg/dl 100–125 mg/dl >126 mg/dl
Glucose2
1 Provisional diabetes diagnosis needs to be confirmed with history and physical
2 Fasting defined as no caloric intake in the last 8 hours
Blood Pressure Blood pressure Systolic Diastolic Classification Chobanian AV, Bakris GL, Black
cuff and (mm Hg) (mm Hg) HR, et al. The Seventh Report of
sphygnomometer < 120 < 80 Normal the Joint National Committee on
120-139 80-89 Pre-Hypertension Prevention, Detection, Evaluation,
140-159 90-99 Stage 1 Hypertension and Treatment of High Blood Pressure
>160 >100 Stage 2 Hypertension JAMA 2003; 289: 2560-2572
Cholesterol Cholestech LDX or Cholesterol Result Classification Grundy SM, Cleeman JI, Merz CN,
any other point-of Type (mg/dl) et al. Implications of recent clinical
care screening Total < 200 Desirable trials for the National
machine Cholesterol 200-239 Borderline high Cholesterol Education Program
> 240 High Adult Treatment Panel III
LDL < 100 Optimal guidelines. Circulation 2004; 110
100-129 Near optimal/Above optimal (2):227-39.
130-159 Borderline high
160-189 High
> 190 Very High
HDL < 40 Undesirable
³ 60 Desirable
Triglycerides < 150 Normal
150-199 Borderline high
200-499 High
³ 500 Very high
Bone Density Achilles Express®, BMD (1) T-score Fracture risk T-score classified by World Health
Achilles InSight®, Normal T > -1.0 Low Organization, however, T-score
QUS-2® Osteopenia T –1 to –2.5 Medium breakdown may vary depending
Osteoporosis T <-2.5 High on ultrasound machine used.
(1) Bone Mineral Density
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Figure 3. Stages of Disease and Prevention Strategies for Diabetes
complexity tests. Examples of tests granted waived status under CLIA
include blood glucose monitoring devices, ovulation tests, and home
drug tests (e.g. marijuana). All waived laboratories must also enroll in
CLIA and pay the applicable fee. Under the good laboratory practices,
CLIA lab procedures must include the following: maintaining a proper
physical environment, follow manufacturers’ instructions, quality
control (QC) procedures, documentation of test results, and proper
disposal of biohazardous waste. California further defines the imple-
mentation of CLIA in Business and Professions Code Section 1244.
Some of the more restrictive provisions require the pharmacist to
establish a supervisory committee consisting of a physician and licensed
laboratory technologist.
The quality control measures required under CLIA could reason-
able include use of control solutions and using correct strip code
numbers for blood glucose meters. If your strip and meter return
a value outside the control solution range, discard the strips and try
another batch before replacing the meter. Better means of ensuring
quality control for blood glucose meters would be to use linearity
solutions that verify your meter’s results over a range of blood
glucose values and parallel testing of clinical samples with labora-
tory values. Your laboratory technologist in your supervisory commit-
tee should be able to conduct the latter testing in their laboratory for
you.
Tertiary Prevention
Unlike primary and secondary prevention, tertiary prevention
includes activities designed to reduce the complications of chronic
diseases. An example of this type of prevention is physical therapy
after an injury or aspirin for post myocardial infarction patients.
Figure 3 illustrates the full spectrum of prevention strategies using
diabetes.
It is clear that from health to disease, we have many chances to
intervene and prevent an individual from going to the next stage. With
the recent focus on medication therapy management, we should
remember the age old adage that “an ounce of prevention is worth a
pound of cure.”
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